The one major mechanism of acquired resistance to targeted therapy is the alterations in the target itself (on-target), such as second mutation T790M in EGFR in EGFR-mutant lung cancer or loss of ER function/expression in ER+ breast cancer. Here, EGFR is linked to breast carcinoma.